AbbVie Inc. (ABBV) Guidance & Earnings Results

On 2026-10-05 AbbVie Inc. issued guidance: "FY26 adjusted EPS $13.76-$13.96 (from $13.87-$14.07); Q3 adjusted EPS…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ABBVAbbVie Inc.Follow ABBV — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 504.8B
P/E TTM: 80.7
Dividend yield: 2.4%
52-week: —
Next earnings: 30 Oct, in 6 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Oct 26	—	FY26 adjusted EPS $13.76-$13.96 (from $13.87-$14.07); Q3 adjusted EPS $3.73-$3.77 · full year
31 Jul 26	Mixed	FY26 adjusted diluted EPS guidance narrowed to $13.87-$14.07 from $13.91-$14.11; includes $0.14 dilutive impact from Apogee acquisition; includes $0.58 unfavorable impact from acquired IPR&D and milestones year-to-date · full year
6 Jul 26	Lowered	Q2 2026 adjusted EPS guidance cut from $3.74-$3.78 to $3.57-$3.61; FY 2026 from $14.08-$14.28 to $13.91-$14.11 · full year
29 Apr 26	Raised	Adjusted EPS guidance raised from $13.96-$14.16 to $14.08-$14.28 · full year
3 Apr 26	Lowered	Full-year adjusted EPS guidance reduced from $14.37-$14.57 to $13.96-$14.16 · full year
4 Feb 26	Raised	2026 adjusted EPS guidance $14.37-$14.57 vs 2025 adjusted EPS $10.00
7 Jan 26	Lowered	Adjusted EPS guidance reduced from $10.61-$10.65 to $9.90-$9.94 · full year
31 Oct 25	Raised	From $10.38-$10.58 to $10.61-$10.65 · full year

AbbVie Inc. — questions

What guidance did AbbVie Inc. give?: On 2026-10-05: "FY26 adjusted EPS $13.76-$13.96 (from $13.87-$14.07); Q3 adjusted EPS $3.73-$3.77"
When does AbbVie Inc. report earnings?: AbbVie Inc.'s next earnings report is expected on 2026-10-30.

Every figure on this page comes from AbbVie Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.